Compare H2O America (HTO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Sana Biotechnology Inc — how do they compare? H2O America trades at $62.3 (market cap $2.61B), while Sana Biotechnology Inc trades at $3.8 (market cap $1.13B). The key difference: H2O America is far larger — about 2.3× Sana Biotechnology Inc's market cap, and H2O America pays a 2.83% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| HTO | SANA | |
|---|---|---|
Market Cap | $2.61B | $1.13B |
Sector | Technology | Health |
52-Week High | $65.43 | $5.92 |
52-Week Low | $44.44 | $2.68 |
Enterprise Value | $4.40B | $1.05B |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $62.57, up 2.16% with bullish technical signals and strong analyst support. The stock shows solid fundamentals with 12.91% net margin and consistent earnings beats in recent quarters. Recent transformative acquisitions in Texas water utilities drive growth potential, though execution risks and share dilution from equity issuance present challenges. Technical indicators show bullish momentum with key resistance at $63 and support at $61.
Outlook remains positive with 83% analyst buy ratings and $69.50 consensus target offering 11% upside. Dividend sustainability and acquisition integration are key watchpoints. Risks include execution challenges from Quadvest deal and potential EPS dilution from recent 11M share issuance.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
